Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfaethoxypyridazine is a synthetic sulfonamide antibacterial agent primarily approved for veterinary use. It is used to treat bacterial infections in animals, such as fowl cholera and salmonella infection. As a member of the sulfonamides, it acts as a structural analogue of para‑aminobenzoic acid (PABA), competitively inhibiting the enzyme dihydropteroate synthase involved in folic acid synthesis. This inhibition disrupts bacterial DNA synthesis and exerts bacteriostatic effects. Sulfaethoxypyridazine is not typically used in humans and is mainly administered to domestic animals and birds[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfaethoxypyridazine.